NMRA Q1 2024 Earnings — Neumora Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

NMRANeumora Therapeutics, Inc. Common Stock

$586M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$60M

Net Income

-$54M

EPS (Diluted)

$-0.34

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$43M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$450M

Total Liabilities

$26M

Stockholders' Equity

$425M

Cash & Equivalents

$183M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$60M	-$39M	-53.4%
Net Income	-$54M	-$36M	-50.8%